Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
IPO Year: 2021
Exchange: NASDAQ
Website: veratx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/5/2025 | $75.00 | Buy | H.C. Wainwright |
| 2/4/2025 | $49.00 | Outperform | Wolfe Research |
| 1/28/2025 | $58.00 | Buy | Goldman |
| 11/21/2024 | $70.00 | Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 1/25/2024 | $26.00 | Outperform | Oppenheimer |
| 1/8/2024 | Overweight | Cantor Fitzgerald | |
| 12/18/2023 | $29.00 | Outperform | Raymond James |
| 11/10/2023 | $18.00 → $26.00 | Hold → Buy | Jefferies |
| 8/16/2023 | $27.00 | Buy | Guggenheim |